Skip to main content
Thu, Mar 19, 2026
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
BusinessUnited States2 sourcesNeutral

Annovis Partners With Neurorpm To Deploy AI-Powered Digital Biomarker Technology In Parkinson's Disease Study

(MENAFN - GlobeNewsWire - Nasdaq) MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (–Annovis– or the–Company–), a Phase 3 clinical-stage biotechnology company ...

Menafn
via Menafn - Corroborated by 1 others

Source Verification

Corroboration Score: 2

This story was independently reported by 2 sources. Click any source to read the original article.

Comments

0 comments
Be respectful and constructive.
Loading comments...